AU2022312494A1 - Antisense oligonucleotide (aso) gene inhibition and treatment - Google Patents

Antisense oligonucleotide (aso) gene inhibition and treatment Download PDF

Info

Publication number
AU2022312494A1
AU2022312494A1 AU2022312494A AU2022312494A AU2022312494A1 AU 2022312494 A1 AU2022312494 A1 AU 2022312494A1 AU 2022312494 A AU2022312494 A AU 2022312494A AU 2022312494 A AU2022312494 A AU 2022312494A AU 2022312494 A1 AU2022312494 A1 AU 2022312494A1
Authority
AU
Australia
Prior art keywords
aso
seq
jak2
ighmbp2
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022312494A
Other languages
English (en)
Other versions
AU2022312494A9 (en
Inventor
Bartlomiej PRZYCHODZEN
Sandra SMIESZEK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of AU2022312494A1 publication Critical patent/AU2022312494A1/en
Publication of AU2022312494A9 publication Critical patent/AU2022312494A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022312494A 2021-07-15 2022-07-13 Antisense oligonucleotide (aso) gene inhibition and treatment Pending AU2022312494A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163222336P 2021-07-15 2021-07-15
US63/222,336 2021-07-15
US202163224362P 2021-07-21 2021-07-21
US63/224,362 2021-07-21
PCT/US2022/073668 WO2023288240A1 (en) 2021-07-15 2022-07-13 Antisense oligonucleotide (aso) gene inhibition and treatment

Publications (2)

Publication Number Publication Date
AU2022312494A1 true AU2022312494A1 (en) 2024-01-18
AU2022312494A9 AU2022312494A9 (en) 2024-01-25

Family

ID=82850241

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022312494A Pending AU2022312494A1 (en) 2021-07-15 2022-07-13 Antisense oligonucleotide (aso) gene inhibition and treatment

Country Status (8)

Country Link
EP (1) EP4370133A1 (https=)
JP (1) JP2024525837A (https=)
KR (1) KR20240037996A (https=)
AU (1) AU2022312494A1 (https=)
CA (1) CA3224471A1 (https=)
IL (1) IL309813A (https=)
MX (1) MX2024000636A (https=)
WO (1) WO2023288240A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121039279A (zh) * 2023-05-05 2025-11-28 万达制药公司 反义寡核苷酸(aso)基因抑制和治疗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014161046A1 (en) * 2013-04-04 2014-10-09 The Walter And Eliza Hall Institute Of Medical Research Methods of treating diseases characterized by excessive wnt signalling
WO2017214463A1 (en) * 2016-06-09 2017-12-14 The Regents Of The University Of California Compositions and methods for treating cancer and biomarkers to detect cancer stem cell reprogramming and progression

Also Published As

Publication number Publication date
AU2022312494A9 (en) 2024-01-25
MX2024000636A (es) 2024-02-06
WO2023288240A8 (en) 2023-12-14
JP2024525837A (ja) 2024-07-12
EP4370133A1 (en) 2024-05-22
KR20240037996A (ko) 2024-03-22
CA3224471A1 (en) 2023-01-19
WO2023288240A1 (en) 2023-01-19
IL309813A (en) 2024-02-01
WO2023288240A9 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
WO2020106876A2 (en) Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease
AU2022312494A1 (en) Antisense oligonucleotide (aso) gene inhibition and treatment
US12036281B2 (en) Method of administering Lapatinib to a canine to treat bladder cancer harboring a BRAF mutation
US20240376478A1 (en) Antisense Oligonucleotide (ASO) Gene Inhibition and Treatment
CN117897161A (zh) 反义寡核苷酸(aso)基因抑制和治疗
US11951178B2 (en) Methods for treating subjects suffering from acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles
US20220220486A1 (en) Combination treatments for cystic fibrosis characterized by a 3849 + 10kb c-to-t cftr mutation
JP2024529930A (ja) 低減されたオフターゲット効果を有する修飾低分子干渉ｒｎａ分子
RU2469737C1 (ru) Способ лечения хронического риносинусита
CN121039279A (zh) 反义寡核苷酸(aso)基因抑制和治疗
CN117043339A (zh) 用于治疗认知障碍的微小rna 195组合物和方法
JP2002537224A (ja) ＮＦ−κＢ活性化阻害剤及びそれらの医薬としての使用
JP7812535B2 (ja) 新型コロナウイルス感染症後遺症治療薬のスクリーニング方法及び新型コロナウイルス感染症後遺症モデル動物の製造方法
US20220184029A1 (en) Compositions and methods for treating neuroblastoma
CN1501976A (zh) 用于联合治疗的crf2配体
KR101693186B1 (ko) ＰＡＮ-ＥｒｂＢ 억제제의 암 치료 효과 예측에 관한 정보 제공 방법
CN112654706B (zh) 靶向淋巴细胞活化基因3(lag-3)的核酸适体及其用途
US20220002726A1 (en) Methods of safe administration of an irf5 antisense oligonucleotide
TW202440100A (zh) 用於治療由csf-1r調節的疾病的給藥方案
KR20250027480A (ko) 스트레스 과립 형성 억제제를 유효성분으로 포함하는 결핵의 예방 또는 치료용 약학 조성물
CN121001742A (zh) 用于癌症的mtor治疗剂
Öztoprak et al. Comparative Transcriptome Analysis Identifies Target Genes for Treatment of IDH Wild-type Lower-grade Gliomas
Zagozewski et al. PDTM-28. AN OTX2-PAX3 SIGNALLING AXIS REGULATES GROUP 3 MEDULLOBLASTOMA CELL FATE
WO2025068557A1 (en) Antisense oligonucleotides for the treatment of canavan disease
KR20250009923A (ko) Gap43 활성 또는 발현을 조절하기 위한 조성물

Legal Events

Date Code Title Description
SREP Specification republished